ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Intercept to Cut 25% of Workforce after NASH Treatment Rejection from FDA americanpharmaceuticalreview
September 07, 2020Intercept Pharmaceuticals plans to lay off 25% of its workforce, approximately 170 jobs, after its nonalcoholic steatohepatitis (NASH) treatment application for obeticholic acid (OCA) was rejected by the U.S. Food and Drug Administration (FDA).
Pharma Sources Insight January 2025
